Sharon McGonigle

Vice President, R&D

Professional Overview
Sharon McGonigle is an accomplished R&D executive with over 15 years of experience in the pharmaceutical and biotechnology industries. As the Vice President of R&D at Solid Biosciences, she leads a team of scientists and researchers focused on developing innovative therapies for rare genetic disorders.

Experience Summary

Current Role
In her current role as Vice President of R&D at Solid Biosciences, Sharon is responsible for overseeing all research and development activities, managing a team of 30+ scientists, and driving the company's pipeline of promising drug candidates. Under her leadership, Solid Biosciences has secured several key regulatory milestones and advanced multiple programs into late-stage clinical trials.

Career Progression
Prior to joining Solid Biosciences, Sharon held several senior-level positions at Eisai Inc., where she progressed from Senior Research Investigator to Senior Principal Scientist over the course of 12 years. In these roles, she made significant contributions to the development of novel therapeutics, including two drug candidates that received FDA approval. Before Eisai, Sharon was a Senior Research Investigator at Surface Logix, where she played a crucial role in advancing the company's drug discovery efforts.

Academic Background
Sharon holds a Ph.D. in Biochemistry from the Massachusetts Institute of Technology, where she specialized in protein structure and function. She also earned a Bachelor of Science degree in Chemistry from the University of Massachusetts Amherst, graduating summa cum laude.

Areas of Expertise

• Rare genetic disease research and drug development

• Innovative therapeutic modalities, including gene therapies and oligonucleotides

• Preclinical and clinical study design and management

• Cross-functional team leadership and scientific collaboration

• Strategic planning and portfolio optimization

Professional Impact
Throughout her career, Sharon has been recognized for her scientific contributions and industry leadership. She has authored numerous peer-reviewed publications and presentations, and serves on the scientific advisory boards of several rare disease patient advocacy organizations. Under her guidance, Solid Biosciences has secured multiple grants and partnerships to accelerate its pipeline development efforts.

Conclusion
With her extensive experience, deep scientific expertise, and proven track record of driving successful drug development programs, Sharon McGonigle is a highly valued leader in the biopharmaceutical industry. In her current role as Vice President of R&D at Solid Biosciences, she is poised to continue making a significant impact on the lives of patients with rare genetic disorders.